Clinical Trial Update: Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 trial investigating intravenous immunoglobulin (IVIg) for Parvovirus B19–mediated cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Diseases
• Parvovirus B19 Associated Cardiomyopathy

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)

Snippet

Sponsor: Prothya Biosolutions | Conditions: Myocardial Diseases, Parvovirus B19, Human | Phase 3 | Status: COMPLETED